RE: Nasdaq28 May 2024 09:20
We have reached saturation, Big investors sold early, bought the cheap seats there's not enough demand on the Nasdaq to rebound. Once there is enough data to get the FDA rolling, things will get better. But atm its a grey area, with Traumakine becoming a distant memory. Its a high risk pharma play, until it isn't. So yeah Faron are going through the hoops. Although it would be nice to support the shareholders, I am happier they are not razzle dazzling it.